Is there a need for another inhalative β2-agonist besides formoterol in patients with asthma?

Respiration

Volumn 68, Issue 4, 2001, Pages 432-437

  Matthys, Heinrich ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Asthma; Inhaled agonists

Indexed keywords

ATMADISC; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DISCUS; FENOTEROL; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORADIL P; FORMOTEROL; FORMOTEROL FUMARATE; GLUCOCORTICOID; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MIFLONIDE; SALBUTAMOL; SALMETEROL; SERETIDE FORTE; SERETIDE MITE; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE;

AEROSOL; ARTICLE; ASTHMA; CLINICAL TRIAL; DEVICE; DIAGNOSTIC TEST; DISEASE CONTROL; DISEASE SEVERITY; DRUG CHOICE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; INSPIRATORY CAPACITY; PRIORITY JOURNAL; PROPHYLAXIS; STEROID THERAPY; SUSTAINED RELEASE PREPARATION; VITAL CAPACITY;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANTI-INFLAMMATORY AGENTS; ASTHMA; DRUG THERAPY, COMBINATION; ETHANOLAMINES; GLUCOCORTICOIDS; HUMANS;

EID: 0034912706     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050543     Document Type: Article

References (63)

1. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells
2. Efficacy and safety of inhaled corticosteroids. New developments
3. Inhaled dry powder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency
4. 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration
5. 2-adrenoceptor agonist. Acute studies of selectivity and duration of effects from salmeterol and salbutamol in healthy subjects
6. Onset and duration of action of single doses of formoterol inhaled via Turbohaler®
7. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic
8. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease
9. Formoterol via Turbuhaler® gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents
10. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children
11. Duration of action of formoterol and salbutamol drypowder inhalation in prevention of exercise-induced asthma in children
12. Evidence of the rapid protective effect of formoterol dry-powder inhalation against exercise-induced bronchospasm in athletes with asthma
13. Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma
14. Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma
15. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients
16. Protective effect of formoterol against the late-phase asthmatic response to allergen
17. Regular inhaled β-agonist treatment in bronchial asthma
18. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol
19. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity
20. Regular formoterol treatment in mild asthma: Effect of bronchial responsiveness during and after treatment
21. The beneficial effect of formoterol compared with salbutamol and salmeterol in acute induced severe bronchoconstriction
22. The use of β-agonists and the risk of death and near death from asthma
23. Inhaled β-agonists: Weighing risks and benefits
24. Regular inhaled salbutamol and airway responsiveness to allergen
25. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol
26. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
27. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids
28. Additive effects of inhaled formoterol and budesonide in reducting asthma exacerbations
29. Effect of inhaled formoterol and budesonide on exacerbations of asthma
30. Exacerbations of asthma
31. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma
32. 2-agonist
33. Formoterol 90 μg via Turbuhaler® was safe in patients with acute bronchoconstriction
34. Formoterol was more cost-effective in a modelling study than terbutaline in as needed treatment of patients with moderate asthma
35. Clinical experience over five years of daily therapy with formoterol in patients with bronchial asthma
36. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol
37. Low dose formoterol Turbuhaler® (Oxis®) b.i.d. a 3-month placebo-controlled comparison with terbutaline (q.i.d.)
38. Comparison of efficacy and safety of formoterol with terbutaline in children with mild to moderate asthma
39. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma
40. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma
41. Serevent nationwide surveillance study: Comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment
42. Potential masking effects of Salmeterol on airway inflammation in asthma
43. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)
44. 2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma
45. Identifying patients at risk from the use of beta-adrenergic agonists
46. 2 adrenoceptor polymorphism
47. Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily in treating moderate to severe asthma
48. Bronchodilators and acute cardiac death
49. Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma
50. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia
51. On the relative therapeutic index between formoterol Turbuhaler and salbutamol pressurized metered dose (pMDI) inhaler in asthmatic patients
52. Tolerability of inhaled high doses of formoterol and salbutamol in asthmatic patients maintained on twice daily formoterol 12 μg (9 μg delivered)
53. Tolerability to high doses of formoterol and terbutaline via Turbohaler® for 3 days in stable asthmatic patients
54. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects
55. Why are long-acting beta-adrenoceptor agonists long acting?
56. The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations
57. Risk of emergency care, hospitalization, and ICU stays of acute asthma among recipients of salmeterol
58. Bronchodilating effect of formoterol but not of salmeterol in two asthmatic patients
59. Different bronchodilating effect of salmeterol and formoterol in an adult asthmatic
60. 2-sympathomimetika zur langzeittherapie des asthma bronchiale. Stellungnahme eines expertengremiums
61. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells
62. 1-agonist formoterol activates the glucocorticoid receptor in vivo